Janssen submits NDA to FDA for first darunavir-based single tablet regimen for HIV-1
Janssen announced submission of a NDA to the FDA for darunavir 800mg/cobicistat 150mg/emtricitabine 200mg/tenofovir alafenamide 10mg, a complete, once daily regimen being investigated for treatment of HIV-1 infection in adults and pediatric patients aged 12 years and older. September 25, 2017